VISIPAQUE 270 Drug Patent Profile

Which patents cover Visipaque 270, and when can generic versions of Visipaque 270 launch?

Visipaque 270 is a drug marketed by Ge Healthcare and is included in two NDAs.

The generic ingredient in VISIPAQUE 270 is iodixanol. There are two drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the iodixanol profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Visipaque 270

A generic version of VISIPAQUE 270 was approved as iodixanol by HENGRUI PHARMA on May 19^th, 2022.

Summary for VISIPAQUE 270

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	73
Clinical Trials:	31
Patent Applications:	3,989
DailyMed Link:	VISIPAQUE 270 at DailyMed

Recent Clinical Trials for VISIPAQUE 270

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Institute of Liver and Biliary Sciences, India	N/A
Guerbet	Phase 1
University of Washington	Phase 1

See all VISIPAQUE 270 clinical trials

Pharmacology for VISIPAQUE 270

Drug Class	Radiographic Contrast Agent
Mechanism of Action	X-Ray Contrast Activity

US Patents and Regulatory Information for VISIPAQUE 270

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ge Healthcare	VISIPAQUE 270	iodixanol	INJECTABLE;INJECTION	020351-001	Mar 22, 1996	AP	RX	Yes	Yes
Ge Healthcare	VISIPAQUE 270	iodixanol	INJECTABLE;INJECTION	020808-001	Aug 29, 1997		DISCN	No	No

Expired US Patents for VISIPAQUE 270

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ge Healthcare	VISIPAQUE 270	iodixanol	INJECTABLE;INJECTION	020808-001	Aug 29, 1997	4,396,597
Ge Healthcare	VISIPAQUE 270	iodixanol	INJECTABLE;INJECTION	020351-001	Mar 22, 1996	4,278,654
Ge Healthcare	VISIPAQUE 270	iodixanol	INJECTABLE;INJECTION	020808-001	Aug 29, 1997	RE36418
Ge Healthcare	VISIPAQUE 270	iodixanol	INJECTABLE;INJECTION	020808-001	Aug 29, 1997	4,278,654

International Patents for VISIPAQUE 270

See the table below for patents covering VISIPAQUE 270 around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	20733
Belgium	877443
Jordan	1619
Luxembourg	88639

Supplementary Protection Certificates for VISIPAQUE 270

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0108638	97C0101	Belgium		PRODUCT NAME: IODIXANOL; NAT. REGISTRATION NO/DATE: 914 IS 204 F 12 19970325; FIRST REGISTRATION: SE 11758 19930205
0108638	SPC/GB93/150	United Kingdom		SPC/GB93/150, 20031107, EXPIRES: 20080330

VISIPAQUE 270 Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for VISIPAQUE 270

Introduction to VISIPAQUE 270

VISIPAQUE 270, also known as iodixanol, is a non-ionic, iso-osmolar radiographic contrast medium used in various medical imaging procedures. It is manufactured by GE Healthcare and is indicated for multiple intra-arterial and intravenous procedures in adults and pediatric patients[4].

Market Indications and Uses

VISIPAQUE 270 is versatile in its applications, including digital subtraction angiography, CT scanning of the head and body, excretory urography, and peripheral venography. This broad range of indications makes it a valuable asset in diagnostic and interventional procedures, contributing to its market demand[5].

Competitive Landscape

The market for radiographic contrast media is competitive, with several other agents available. However, VISIPAQUE 270 stands out due to its iso-osmolar properties, which reduce the risk of adverse reactions such as pain, heat, and burning sensations upon injection. This unique characteristic positions it favorably against other contrast agents, particularly in patients with compromised renal function or other risk factors[1][4].

Patient Population and Market Size

Given the increasing prevalence of conditions requiring diagnostic imaging, such as cardiovascular diseases, diabetes, and various cancers, the demand for contrast agents like VISIPAQUE 270 is on the rise. For instance, by 2060, it is projected that 1 in 4 people in the US will be aged 65+, a demographic that often requires more frequent medical imaging procedures[4].

Pricing and Cost Considerations

The pricing of VISIPAQUE 270 varies depending on the formulation and packaging. For example, the cost per milliliter for VISIPAQUE 270 can range from $1.13 to $1.57 USD, depending on whether it is purchased in vials or cartridges[3].

Financial Performance and Revenue

While specific revenue figures for VISIPAQUE 270 are not publicly disclosed, the overall market for contrast agents is substantial. The demand for these agents is driven by the growing need for diagnostic imaging, which in turn is fueled by an aging population and an increase in chronic diseases. GE Healthcare, the manufacturer of VISIPAQUE, benefits from this trend, contributing to its financial stability and growth in the healthcare sector.

Regulatory Environment

The regulatory environment plays a crucial role in the market dynamics of VISIPAQUE 270. The drug is subject to strict regulations and must comply with FDA guidelines. Any changes in regulatory policies or the approval of new contrast agents can impact the market share of VISIPAQUE 270. However, its established safety profile and efficacy have helped it maintain a strong position in the market[5].

Clinical Trials and Research

Continuous research and clinical trials are essential for maintaining and expanding the indications for VISIPAQUE 270. These studies help in understanding the drug's safety and efficacy in various patient populations, which can lead to new market opportunities. For instance, studies focusing on patients with renal dysfunction have highlighted the benefits of using VISIPAQUE 270, further solidifying its market position[3].

Patient Safety and Adverse Reactions

The safety profile of VISIPAQUE 270 is a critical factor in its market dynamics. The drug is generally well-tolerated, but like all contrast agents, it can cause adverse reactions such as acute kidney injury, thromboembolic events, and hypersensitivity reactions. Ensuring patient safety through proper use and monitoring is essential for maintaining market trust and compliance[5].

Market Trends and Future Outlook

The future outlook for VISIPAQUE 270 is positive, driven by advancements in medical imaging technologies and the increasing need for diagnostic procedures. The trend towards personalized medicine and the integration of AI in healthcare will likely increase the demand for high-quality contrast agents like VISIPAQUE 270.

Key Trends:

• Aging Population: The increasing age of the population will drive the demand for diagnostic imaging procedures.
• Technological Advancements: Improvements in imaging technologies will enhance the utility and demand for contrast agents.
• Personalized Medicine: Tailored diagnostic approaches will require precise and safe contrast agents.

Financial Projections

Given the stable demand and the expanding indications for VISIPAQUE 270, financial projections indicate continued growth. Here are some key financial metrics:

Revenue Growth:

• The market for contrast agents is expected to grow at a steady rate, driven by the increasing need for diagnostic imaging.
• VISIPAQUE 270, with its unique properties, is likely to capture a significant share of this growing market.

Cost Management:

• Efficient production and distribution strategies will be crucial in managing costs and maintaining profitability.
• GE Healthcare's global reach and manufacturing capabilities will help in optimizing costs.

Investment Opportunities:

• Continued investment in research and development to expand indications and improve safety profiles will be essential.
• Strategic partnerships and collaborations can further enhance market penetration.

Key Takeaways

• Market Indications: VISIPAQUE 270 is used in a wide range of diagnostic and interventional procedures.
• Competitive Advantage: Its iso-osmolar properties reduce adverse reactions, making it a preferred choice.
• Patient Population: The growing need for diagnostic imaging in an aging population drives demand.
• Financial Performance: The drug contributes significantly to GE Healthcare's revenue, with a positive growth outlook.
• Regulatory Compliance: Adherence to regulatory guidelines is crucial for market stability.

FAQs

1. What is VISIPAQUE 270 used for?

VISIPAQUE 270 is used for various medical imaging procedures, including digital subtraction angiography, CT scanning of the head and body, excretory urography, and peripheral venography[5].

2. What are the unique properties of VISIPAQUE 270?

VISIPAQUE 270 is an iso-osmolar, isotonic contrast agent, which reduces the risk of adverse reactions such as pain, heat, and burning sensations upon injection[1].

3. Who manufactures VISIPAQUE 270?

VISIPAQUE 270 is manufactured by GE Healthcare[4].

4. What are the common adverse reactions associated with VISIPAQUE 270?

Common adverse reactions include rash, erythema, pruritus, scotoma, acute kidney injury, thromboembolic events, and hypersensitivity reactions[5].

5. How does the pricing of VISIPAQUE 270 compare to other contrast agents?

The pricing of VISIPAQUE 270 varies but generally falls within a competitive range compared to other contrast agents, with costs ranging from $1.13 to $1.57 USD per milliliter[3].

Sources:

1. Product Monograph VISIPAQUE (iodixanol injection USP) - PDF.
2. Visipaque 270 | Drug Information, Uses, Side Effects, Chemistry - PharmaCompass.
3. Iodixanol: Uses, Interactions, Mechanism of Action | DrugBank Online - DrugBank.
4. Visipaque™ (iodixanol) injection | GE HealthCare (United States) - GE HealthCare.
5. VISIPAQUE 270 Prescription & Dosage Information - eMPR.com - eMPR.